Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...

A study led by USC Assistant Professor of Computer Science Ruishan Liu has uncovered how specific genetic mutations influence ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

The research uncovers key genetic mutations that affect cancer treatment responses and develops a predictive tool for ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Elicio Therapeutics aims for breakthrough treatment with ELI-002 in pancreatic cancer. Find out why ELTX stock may benefit ...

为了进一步提高KRAS G12C突变患者的治疗效果，研究团队设计了一项临床试验。他们尝试将靶向药索托拉西布与传统化疗（卡铂和培美曲塞）相结合，用于治疗晚期非鳞状非小细胞肺癌患者。